Biomarkers ID CHF Patients Needing Medication Titration

Share this content:
Using biomarkers to titrate CHF meds may better improve mortality vs. generic titration of all patients
Using biomarkers to titrate CHF meds may better improve mortality vs. generic titration of all patients

(HealthDay News) -- Using biomarkers to identify heart failure patients for up-titration of medications may improve mortality and hospitalization rates, according to a study published in the Journal of the American College of Cardiology.

Wouter Ouwerkerk, PhD, from the University of Amsterdam, and colleagues compared clinical outcomes of 2516 patients with worsening heart failure participating in the BIOSTAT-CHF (BIOlogy Study to Tailored Treatment in Chronic Heart Failure) based upon 3 theoretical treatment scenarios: scenario A, in which all patients are up-titrated to >50% of recommended doses; scenario B, in which patients are up-titrated according to a biomarker-based treatment selection; and scenario C, in which no patient is up-titrated to >50% of recommended doses.

The researchers found that for 1802 patients with available biomarker data, estimated death or hospitalization rates were 16, 16, and 26%, respectively, in the angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB) up-titration scenarios A, B, and C. In the 3 scenarios, rates with beta-blocker and mineralocorticoid receptor antagonist (MRA) up-titration were 23, 19, and 24% and 12, 11, and 24%, respectively. At 24 months, an estimated 9.8, 1.3, and 12.3 events per 100 treated patients could be prevented by ACE inhibitor/ARB, beta-blocker, and MRA therapy, respectively, if up-titration was successful in all patients. Events prevented were similar if up-titration treatment decision was based on a biomarker-based treatment selection model.

"Up-titrating patients with heart failure based on biomarker values might have resulted in fewer deaths or hospitalizations compared with a hypothetical scenario in which all patients were successfully up-titrated," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Reference

Wouter Ouwerkerk, Aeilko H. Zwinderman, Leong L. Ng, et al. Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure Results From BIOSTAT-CHF. J Am Coll Cardiol. 2018 Jan;71(4). DOI:10.1016/j.jacc.2017.11.041.

You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup